TNF Pharmaceuticals, Inc. TNFA · Stock Open TNF Pharmaceuticals, Inc. in new tab
TNF Pharmaceuticals, Inc. Analysis (TNFA)
Is TNF Pharmaceuticals, Inc. a good investment? TNF Pharmaceuticals, Inc. (TNFA) is currently trading at 5.20 USD.
Earnings Schedule: TNF Pharmaceuticals, Inc. is expected to release its next earnings report on Nov. 13, 2025.
Investor FAQ
Does TNF Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is TNF Pharmaceuticals, Inc.?
TNF Pharmaceuticals, Inc. is classified as a Stock.
When is the next earnings date?
The next earnings date is projected to be Nov. 13, 2025. The company currently has a trailing EPS of -202.00.
Company Profile
Q/C Technologies, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog of derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. The company has a strategic alliance with DADA2 Foundation for research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2). The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.
| Split Date | Split Ratio to 1 |
|---|---|
| Nov. 8, 2018 | Needs review |
| Nov. 25, 2019 | 0.040000 |
| April 19, 2021 | 0.500000 |
| Feb. 15, 2024 | 0.030000 |
| Sept. 2, 2025 | 0.010000 |
Community Discussion